The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum β-lactamases in Escherichia coli

Tisha C. Netzel, Irfan Jindani, Nancy D. Hanson, Bradley M. Turner, L. Smith, Kenneth H. Rand

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

AmpC β-lactamases are not inhibited by clavulanic acid and could potentially mask detection of extended-spectrum β-lactamases (ESBLs) using the Clinical and Laboratory Standards Institute confirmatory test. Syn2190 (1,5-dihydroxy-4-pyridone monobactam) selectively inhibits AmpC, but not ESBLs. Fifty-four MicroScan ESBL screen-positive strains of Escherichia coli and an unrelated group of 20 cefoxitin-nonsusceptible E. coli strains were tested with the confirmatory ceftazidime-cefotaxime-clavulanate disk method with or without 4 μg/mL of Syn2190 in the agar. Without Syn2190, 8 (14.8%) of 54 E. coli isolates and 0 of 20 cefoxitin-nonsusceptible E. coli isolates were confirmed. With Syn2190, an additional 9 (16.6%) of 54 of the MicroScan screen-positive E. coli isolates and 6 (30%) of 20 of the cefoxitin-nonsusceptible E. coli isolates were found. Multiplex polymerase chain reaction and sequence analysis confirmed the presence of the plasmid-associated β-lactamase gene blaCMY-2 in the 2 available MicroScan-screened E. coli isolates and in 5 of 6 of the cefoxitin-resistant group. These data suggest that in the presence of AmpC, ESBLs in E. coli may not be detected by the currently recommended confirmatory test.

Original languageEnglish
Pages (from-to)345-348
Number of pages4
JournalDiagnostic Microbiology and Infectious Disease
Volume58
Issue number3
DOIs
StatePublished - Jul 2007

Fingerprint

Escherichia coli
Cefoxitin
Clavulanic Acid
Monobactams
Ceftazidime
Cefotaxime
Syn 2190
Multiplex Polymerase Chain Reaction
Masks
Agar
Sequence Analysis
Plasmids
Genes

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Immunology and Allergy
  • Virology
  • Parasitology
  • Microbiology
  • Immunology
  • Applied Microbiology and Biotechnology

Cite this

The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum β-lactamases in Escherichia coli. / Netzel, Tisha C.; Jindani, Irfan; Hanson, Nancy D.; Turner, Bradley M.; Smith, L.; Rand, Kenneth H.

In: Diagnostic Microbiology and Infectious Disease, Vol. 58, No. 3, 07.2007, p. 345-348.

Research output: Contribution to journalArticle

Netzel, Tisha C. ; Jindani, Irfan ; Hanson, Nancy D. ; Turner, Bradley M. ; Smith, L. ; Rand, Kenneth H. / The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum β-lactamases in Escherichia coli. In: Diagnostic Microbiology and Infectious Disease. 2007 ; Vol. 58, No. 3. pp. 345-348.
@article{de1807e0f5814ea8b29be78eb35fee9c,
title = "The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum β-lactamases in Escherichia coli",
abstract = "AmpC β-lactamases are not inhibited by clavulanic acid and could potentially mask detection of extended-spectrum β-lactamases (ESBLs) using the Clinical and Laboratory Standards Institute confirmatory test. Syn2190 (1,5-dihydroxy-4-pyridone monobactam) selectively inhibits AmpC, but not ESBLs. Fifty-four MicroScan ESBL screen-positive strains of Escherichia coli and an unrelated group of 20 cefoxitin-nonsusceptible E. coli strains were tested with the confirmatory ceftazidime-cefotaxime-clavulanate disk method with or without 4 μg/mL of Syn2190 in the agar. Without Syn2190, 8 (14.8{\%}) of 54 E. coli isolates and 0 of 20 cefoxitin-nonsusceptible E. coli isolates were confirmed. With Syn2190, an additional 9 (16.6{\%}) of 54 of the MicroScan screen-positive E. coli isolates and 6 (30{\%}) of 20 of the cefoxitin-nonsusceptible E. coli isolates were found. Multiplex polymerase chain reaction and sequence analysis confirmed the presence of the plasmid-associated β-lactamase gene blaCMY-2 in the 2 available MicroScan-screened E. coli isolates and in 5 of 6 of the cefoxitin-resistant group. These data suggest that in the presence of AmpC, ESBLs in E. coli may not be detected by the currently recommended confirmatory test.",
author = "Netzel, {Tisha C.} and Irfan Jindani and Hanson, {Nancy D.} and Turner, {Bradley M.} and L. Smith and Rand, {Kenneth H.}",
year = "2007",
month = "7",
doi = "10.1016/j.diagmicrobio.2007.01.017",
language = "English",
volume = "58",
pages = "345--348",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - The AmpC inhibitor, Syn2190, can be used to reveal extended-spectrum β-lactamases in Escherichia coli

AU - Netzel, Tisha C.

AU - Jindani, Irfan

AU - Hanson, Nancy D.

AU - Turner, Bradley M.

AU - Smith, L.

AU - Rand, Kenneth H.

PY - 2007/7

Y1 - 2007/7

N2 - AmpC β-lactamases are not inhibited by clavulanic acid and could potentially mask detection of extended-spectrum β-lactamases (ESBLs) using the Clinical and Laboratory Standards Institute confirmatory test. Syn2190 (1,5-dihydroxy-4-pyridone monobactam) selectively inhibits AmpC, but not ESBLs. Fifty-four MicroScan ESBL screen-positive strains of Escherichia coli and an unrelated group of 20 cefoxitin-nonsusceptible E. coli strains were tested with the confirmatory ceftazidime-cefotaxime-clavulanate disk method with or without 4 μg/mL of Syn2190 in the agar. Without Syn2190, 8 (14.8%) of 54 E. coli isolates and 0 of 20 cefoxitin-nonsusceptible E. coli isolates were confirmed. With Syn2190, an additional 9 (16.6%) of 54 of the MicroScan screen-positive E. coli isolates and 6 (30%) of 20 of the cefoxitin-nonsusceptible E. coli isolates were found. Multiplex polymerase chain reaction and sequence analysis confirmed the presence of the plasmid-associated β-lactamase gene blaCMY-2 in the 2 available MicroScan-screened E. coli isolates and in 5 of 6 of the cefoxitin-resistant group. These data suggest that in the presence of AmpC, ESBLs in E. coli may not be detected by the currently recommended confirmatory test.

AB - AmpC β-lactamases are not inhibited by clavulanic acid and could potentially mask detection of extended-spectrum β-lactamases (ESBLs) using the Clinical and Laboratory Standards Institute confirmatory test. Syn2190 (1,5-dihydroxy-4-pyridone monobactam) selectively inhibits AmpC, but not ESBLs. Fifty-four MicroScan ESBL screen-positive strains of Escherichia coli and an unrelated group of 20 cefoxitin-nonsusceptible E. coli strains were tested with the confirmatory ceftazidime-cefotaxime-clavulanate disk method with or without 4 μg/mL of Syn2190 in the agar. Without Syn2190, 8 (14.8%) of 54 E. coli isolates and 0 of 20 cefoxitin-nonsusceptible E. coli isolates were confirmed. With Syn2190, an additional 9 (16.6%) of 54 of the MicroScan screen-positive E. coli isolates and 6 (30%) of 20 of the cefoxitin-nonsusceptible E. coli isolates were found. Multiplex polymerase chain reaction and sequence analysis confirmed the presence of the plasmid-associated β-lactamase gene blaCMY-2 in the 2 available MicroScan-screened E. coli isolates and in 5 of 6 of the cefoxitin-resistant group. These data suggest that in the presence of AmpC, ESBLs in E. coli may not be detected by the currently recommended confirmatory test.

UR - http://www.scopus.com/inward/record.url?scp=34347350006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347350006&partnerID=8YFLogxK

U2 - 10.1016/j.diagmicrobio.2007.01.017

DO - 10.1016/j.diagmicrobio.2007.01.017

M3 - Article

VL - 58

SP - 345

EP - 348

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 3

ER -